CEACAM5 and cancer: A variety of tumor-specific and tumor-associated antigens that can be targeted using CAR T cell therapy in non-hematopoietic malignancies have been identified (e.g., EGFR/EGFRvIII, IL13Rα2, Her2, CD171, mesothelin (MSLN), folate receptor alpha, GD2, carcinoembryonic antigen (CEA), chondroitin sulfate proteoglycan 4, c-Met, etc.).